SIBN vs. OFIX, SRDX, CRY, ANIK, XENT, UFPT, LMAT, ATEC, ATRC, and MDXG
Should you be buying SI-BONE stock or one of its competitors? The main competitors of SI-BONE include Orthofix Medical (OFIX), Surmodics (SRDX), CryoLife (CRY), Anika Therapeutics (ANIK), Intersect ENT (XENT), UFP Technologies (UFPT), LeMaitre Vascular (LMAT), Alphatec (ATEC), AtriCure (ATRC), and MiMedx Group (MDXG).
SI-BONE (NASDAQ:SIBN) and Orthofix Medical (NASDAQ:OFIX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.
SI-BONE has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, Orthofix Medical has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500.
Orthofix Medical has a net margin of -16.64% compared to SI-BONE's net margin of -29.93%. Orthofix Medical's return on equity of -14.24% beat SI-BONE's return on equity.
Orthofix Medical received 251 more outperform votes than SI-BONE when rated by MarketBeat users. However, 67.23% of users gave SI-BONE an outperform vote while only 61.80% of users gave Orthofix Medical an outperform vote.
SI-BONE has higher earnings, but lower revenue than Orthofix Medical. SI-BONE is trading at a lower price-to-earnings ratio than Orthofix Medical, indicating that it is currently the more affordable of the two stocks.
In the previous week, SI-BONE and SI-BONE both had 2 articles in the media. SI-BONE's average media sentiment score of 0.93 beat Orthofix Medical's score of 0.31 indicating that SI-BONE is being referred to more favorably in the media.
SI-BONE presently has a consensus target price of $27.29, suggesting a potential upside of 94.20%. Orthofix Medical has a consensus target price of $18.00, suggesting a potential upside of 31.10%. Given SI-BONE's stronger consensus rating and higher probable upside, research analysts plainly believe SI-BONE is more favorable than Orthofix Medical.
98.1% of SI-BONE shares are owned by institutional investors. Comparatively, 89.8% of Orthofix Medical shares are owned by institutional investors. 5.4% of SI-BONE shares are owned by company insiders. Comparatively, 4.7% of Orthofix Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
SI-BONE beats Orthofix Medical on 11 of the 17 factors compared between the two stocks.
Get SI-BONE News Delivered to You Automatically
Sign up to receive the latest news and ratings for SIBN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SIBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
